Remember meForgot password?
    Log in with Twitter
Press Release

Feb 7, 2018 15:38 UTC

The Journal of Targeted Therapies in Cancer™ Welcomes Robert L. Ferris, M.D., Ph.D., as Editor-in-Chief

CRANBURY, N.J.--(Business Wire)--The Journal of Targeted Therapies in Cancer (JTT), a peer-reviewed journal that aims to enhance patient outcomes by sharing clinical articles in which advances in cancer targets and targeted therapies are analyzed, has appointed Robert L. Ferris, M.D., Ph.D., as its editor-in-chief.

"I am delighted to help lead this exciting and topical journal, to disseminate new findings, and bring together translational and clinical investigators advancing the field of targeted cancer therapies,” said Dr. Ferris.

Ferris will work closely with the editorial team, led by Anthony Berberabe, to raise the impact of JTT in the oncology community as well as offer deep insight on recent advancements in the targeted therapies arena. He will also deliver clinical and investigative articles that concern the oncology arena.

“Dr. Ferris’s incredible experience and contributions in the field of immunology and oncology will not just be beneficial for our team, but also for our audience,” said Michael J. Hennessy Jr., president of Michael J. Hennessy Associates Inc., parent company of Targeted Oncology. “Together, we look forward to building on what we have already achieved.”

Ferris is the director of the University of Pittsburgh Medical Center’s Hillman Cancer Center, the Hillman professor of oncology, associate vice chancellor for cancer research and co-director of the Tumor Microenvironment Center. His research primarily focuses on cellular immune mechanisms of natural killer cells, dendritic cells, and T lymphocyte activation against head and neck cancer tumor antigens. His group also conducts research on mechanisms of tumor antigen processing and immunologic evasion used by head and neck cancer cells.

For more information on JTT and its editorial team, visit

About Targeted Oncology provides the latest news and insight on next-generation therapeutics and their molecular targets for practicing oncologists. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying up-to-date with the future of cancer therapeutics. As such, TargetedOnc strives to provide the latest information on breaking news and updates on the burgeoning field. TargetedOnc focuses on the next stage of cancer development, on cutting edge therapies and their biological targets. Content is organized by tumor type, news and conference coverage.

Targeted Oncology™ Media:
Theresa Burek, 609-716-7777 ext. 811
Surabhi Verma, 609-716-7777 ext. 851